The PARP inhibitor niraparib showed antitumor activity at 300 mg daily with more pronounced hematologic adverse effects compared with olaparib (anemia, thrombocytopenia, and neutropenia) (Sandhu et al. 2013). Here, PARP1 is linked to anemia.